Enovis (ENOV) to Release Earnings on Thursday

Enovis (NYSE:ENOV) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $0.83 per share and revenue of $581.8370 million for the quarter. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. During the same period last year, the business earned $0.81 EPS. The business’s revenue was up 5.4% on a year-over-year basis. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Stock Performance

Shares of ENOV stock opened at $30.18 on Thursday. Enovis has a 12 month low of $19.14 and a 12 month high of $34.28. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The firm has a market capitalization of $1.74 billion, a P/E ratio of -1.52 and a beta of 1.39. The company’s fifty day moving average price is $23.86 and its two-hundred day moving average price is $23.78.

Insiders Place Their Bets

In related news, insider Oliver Engert bought 1,200 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have acquired 4,200 shares of company stock worth $92,084. 2.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enovis

Several large investors have recently modified their holdings of the stock. AQR Capital Management LLC increased its holdings in Enovis by 12.5% in the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after buying an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after buying an additional 73,116 shares in the last quarter. Empowered Funds LLC lifted its holdings in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the last quarter. Finally, Amundi grew its position in shares of Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after acquiring an additional 9,762 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. William Blair initiated coverage on Enovis in a report on Friday, April 17th. They issued an “outperform” rating for the company. Evercore set a $32.00 price objective on Enovis in a research note on Monday, July 6th. Wells Fargo & Company lowered their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, UBS Group reaffirmed a “buy” rating and issued a $51.00 target price (up from $50.00) on shares of Enovis in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $41.86.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.